OTCMKTS:HKMPF Hikma Pharmaceuticals (HKMPF) Stock Price, News & Analysis $22.14 0.00 (0.00%) As of 10/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendNews and TrendsShort Interest About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hikma Pharmaceuticals alerts:Sign Up Key Stats Today's Range$22.14▼$22.1450-Day Range$21.06▼$22.1952-Week Range$16.34▼$24.32VolumeN/AAverage Volume332 shsMarket Capitalization$4.91 billionP/E RatioN/ADividend Yield3.43%Price TargetN/AConsensus RatingModerate Buy Company Overview Hikma Pharmaceuticals plc is a multinational pharmaceutical company that develops, manufactures and markets a broad range of generic, branded and specialty medicines. Its portfolio includes injectable medicines, oral solid-dose products, inhalation products and other treatments used in hospitals, pharmacies and community-care settings. The company operates through three principal businesses: Injectables, Generics and Branded Medicines. Hikma supplies injectable products to hospitals and healthcare providers, offers generic medicines primarily in the United States, and markets branded and licensed medicines across the Middle East and North Africa. It also serves selected European and other international markets. Hikma was founded in 1978 by Samih Darwazah in Amman, Jordan, and has since expanded into a global pharmaceutical group headquartered in London. The company’s leadership includes Executive Chairman Said Darwazah and Chief Executive Officer Siggi Olafsson.AI Generated. May Contain Errors. Read More Receive HKMPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HKMPF Stock News HeadlinesHikma names ViiV finance chief Rebecca Hall as new CFOSeptember 24, 2026 | tipranks.comHikma launches investor spotlight series on R&D strategySeptember 22, 2026 | tipranks.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 25 at 1:00 AM | Porter & Company (Ad)Hikma Executives Reinvest Dividends in Company Shares via DRIPSeptember 22, 2026 | tipranks.comHikma updates market on total voting rights and share capitalSeptember 1, 2026 | tipranks.comHikma completes $250m share buyback, reshaping capital structureAugust 28, 2026 | tipranks.comHikma Executives Restructure Pledges Over 2 Million Shares via DarholdAugust 24, 2026 | tipranks.comHikma Advances $250m Share Buyback, Tightens Free FloatAugust 24, 2026 | tipranks.comSee More Headlines HKMPF Stock Analysis - Frequently Asked Questions How have HKMPF shares performed this year? Hikma Pharmaceuticals' stock was trading at $20.94 at the start of the year. Since then, HKMPF stock has increased by 5.7% and is now trading at $22.1350. How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hikma Pharmaceuticals investors own include Hikma Pharmaceuticals (HIK), Amneal Pharmaceuticals (AMRX), AMERISAFE (AMSF), ArcBest (ARCB), Abbott Laboratories (ABT), AES (AES) and American Financial Group (AFG). Company Calendar Today10/25/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:HKMPF Previous SymbolOTC:HKMPF CIKN/A Webwww.hikma.com Phone442073992760Fax44-20-7399-2761Employees9,400Year Founded1978Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$3.35 billion Price / Sales1.47 Cash Flow$3.34 per share Price / Cash Flow6.63 Book Value$11.74 per share Price / Book1.89Miscellaneous Outstanding Shares221,890,000Free FloatN/AMarket Cap$4.91 billion OptionableNot Optionable Beta0.63 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:HKMPF) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
